Avastin meets endpoint in Phase III second-line breast cancer trial
This article was originally published in Scrip
Executive Summary
Genentech's (Roche) Avastin (bevacizumab) has met its primary progression-free survival (PFS) endpoint in a Phase III trial, RIBBON 2, the first to test it as a second-line treatment in combination with chemotherapy in women with metastatic HER2-negative breast cancer.